<?xml version="1.0" encoding="UTF-8"?>
<p>Given the unique mechanism of immunotherapy, many unconventional phenomena can appear. Pseudoprogression is one such treatment response reported in many tumors treated with immunotherapy (
 <xref rid="B5" ref-type="bibr">5</xref>). Recognizing and understanding this phenomenon is crucial since it may lead to discontinuing therapy in patients that are actually responding positively. Although pseudoprogression can be judged in many ways (
 <xref rid="B6" ref-type="bibr">6</xref>â€“
 <xref rid="B8" ref-type="bibr">8</xref>), it is difficult to quickly distinguish it from real progression. Here, we present a case of RCC metastasized to the lung and brain where significant pseudoprogression appeared twice during treatment with the PD-1 inhibitor nivolumab combined with CIK cells.
</p>
